Skip to main content
OpenTrials
Completed

NCT Number: NCT02703818

SCS for the Treatment Of Chronic Pain of the Upper Extremities

This is a prospective, multi-center post-market study of the Senza System in subjects with chronic, intractable pain of the upper extremities. Data at follow-up visits will be compared to Baseline data collected at the beginning of the study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

NEVRO Corp

Redwood City, California, 94065, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Have been diagnosed with chronic, intractable pain of an upper extremity of neuropathic origin, which has been refractory to conservative therapy for a minimum of 3 months.
  • Have an average pain intensity (over a period of 7 days) of an upper extremity of ≥ 5 out of 10 cm on the Visual Analog Scale (VAS) at enrollment.
  • Be on stable pain medications for at least 28 days and be willing to stay on those medications with no dose adjustments until activation of the permanently implanted SCS device.
  • Be 18 years of age or older at the time of enrollment.
  • Be an appropriate candidate for the surgical procedures required in this study.
  • Be capable of subjective evaluation, able to read and understand English-written questionnaires, and are able to read, understand and sign the written inform consent in English.
  • Have stable neurological status measured by motor, sensory and reflex function.

Key Exclusion Criteria:

  • Have a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures.
  • Have a current diagnosis of a progressive neurological disease.
  • Have a current diagnosis or condition such as a coagulation disorder, bleeding diathesis, platelet dysfunction, progressive peripheral vascular disease or uncontrolled diabetes mellitus that presents excess risk for performing the procedure.
  • Have mechanical spine instability as determined.
  • Have significant stenosis, based on MRI.
  • Have an existing drug pump and/or another active implantable device (switched on or off) such as a pacemaker or other SCS devices.
  • Have a condition currently requiring or likely to require the use of whole body MRI or diathermy.
  • Be pregnant (if female and sexually active, subject must be using a reliable form of birth control, be surgically sterile or be at least 2 years post-menopausal).
  • Have within 6 months of enrollment a significant untreated addiction to dependency producing medications, alcohol or illicit drugs.
  • Be involved in an injury claim under current litigation.
  • Have a pending or approved worker's compensation claim.
  • Have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention and/or ability to evaluate treatment outcome, as determined by a psychologist.

Treatment and study plan

Senza

Device

Spinal Cord Stimulation

Primary outcomes

  1. Responder Rate

    Time frame: 3 months

Sponsors and collaborators

Lead sponsor

Nevro Corp

Industry

Registry information

Official study title

Multi-Center, Prospective, Clinical Trial of the Senza™ Spinal Cord Stimulation (SCS) System in the Treatment Of Chronic Pain of the Upper Extremities

Acronym: UEP

Important dates

Study start
2016
Primary completion
2017
Study completion
2018
First posted
Mar 9, 2016
Registry last updated
Dec 3, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.